Marion Merrell Dow says that the US Federal Trade Commission has asked for additional information under the Hart-Scott-Rodino Antitrust Improvements Act in connection with the proposed acquisition of all of the outstanding shares of MMD by Hoechst Inc, the US subsidiary of the German Hoechst group (Marketletters passim).
The additional information will be provided promptly, according to MMD, which believes the proposed acquisition and merger fully comply with all applicable laws. Under the terms of the HSR Act, the request extends the waiting period until 20 days after the delivery of the requested information to the agency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze